Success examples
RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma

Mozzarelli A. M., Cuevas-Navarro A., Shuldiner E. G., Vega M., Chatila W. K., Xu J., Walch H. S., Niu Y., Petrov D. A., Schultz N., Urisman A., Rudin C. M., Winslow M. M., Castel P.

Cancer Res. 2025, 85(17):3196-3206.

SOS1::KRAS inhibitor
DOI
PubMed
Success examples
Exploring the role of cellular plasticity in metabolic dysfunction-associated steatosis and related molecular mechanisms

Ercin M., Gezginci-Oktayoglu S. J

Transl Med. 2025, 23(1):1278.

GSK-3 inhibitor
DOI
PubMed
Success examples
Native Mass Spectrometry Analysis of Cullin RING Ubiquitin E3 Ligase Complexes in the Context of Targeted Protein Degradation

Sternicki L. M., Crowe C., Wieske L. H. E., Ciulli A., Poulsen S-A.

bioRxiv. 2026, 12.04.692288.

BET PROTAC
DOI
PubMed
Success examples
Systematic Application of a Cellular Thermal Shift Assay for Inferring Inhibitor Binding Affinity to 17βHSD13 in a Humanized Liver Homogenate

Lunnerdal S., Wågberg F., Dahl G., Ahnmark A., Hansson P., Sampers E., Madeyski-Bengtson K., Lee W., Löfgren L., Zarrouki B., Hallén S., Lundbäck T. 

Biochemistry. 2026, 65(3):311-324.

HSD17B13 inhibitor
DOI
PubMed
Success examples
Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting

Damghani T., Song S., Lin K. S., Li J., Heppner D. E.

ACS Medicinal Chemistry Letters 2026.

4th gen EGFR inhibitor
DOI
Success examples
Mixed Lineage Kinase Domain-Like Protein (MLKL): From Mechanisms to Therapeutic Opportunities

Xu L., Zhuang C.

Adv Sci (Weinh). 2025, 12(35):e09277.

MLKL inhibitor
DOI
PubMed